The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 3.25
High: 3.25
Low: 3.25
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: M&C Saatchi pulls Next Fifteen deal support

Fri, 17th Jun 2022 10:46

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Directa Plus PLC, up 10% at 107.00 pence, 12-month range 95.1p-178p. Sees an acceleration in trading in the last two months since the first quarter of the year. The graphene-based product supplier says that revenue from the start of the year to the end of May was approximately 44% ahead of the same period the previous year at EUR4.6 million. Directa Plus says this was driven by growth in all its commercial verticals, with sales in line with expectations.

----------

Bidstack Group PLC, up 6.4% at 2.40p, 12-month range 1.6p-6.15p. The in-game advertising platform hires David Reeves as chair designate to succeed Donald Stewart on September 1. The company says Reeves will serve as a non-executive director in the meantime. Stewart will move to a non-executive role and serve on the audit and remuneration Committees on Reeves' becoming the chair. Reeves has over 30 years' global experience in senior management roles within multinational companies across the video games industry, having working at Sony and Capcom.

----------

AIM - LOSERS

----------

ValiRx PLC, down 12% at 19.15p, 12-month range 17.3p-63p. The drug development company anticipates extension request to the exclusivity period between itself and TheroemRx Inc regarding the proposed sub-licence for VAL201. An exclusivity period was granted to June 30 to enable TheoremRx to progress its financing round, which the sub-licence of VAL201 depends. Progress on financing remains positive, but ValiRx anticipates that an extension to the exclusivity period will be requested and intends to seek "more formal confirmation" of the progress. "The letter of intent and proposed sub-license therefore remain non-binding and there is no guarantee that this sub-license will be executed or that it will generate material revenues within the expected timeframe or at all," it says.

----------

M&C Saatchi PLC, down 7.3% at 164p, 12-month range 122p-227p. Directors pull support for takeover offer by Next Fifteen Communications Group PLC, while still not supporting a rival offer by AdvancedAdvT Ltd. M&C Saatchi directors "no longer consider the terms of the Next 15 offer to be fair and reasonable solely on the basis of the deterioration in value of Next 15 shares since the announcement date," the London-based advertising agency explains. Since announcing its share-based acquisition offer in May, Next Fifteen shares have fallen by around 30%. M&C Saatchi, however, also warns that it may be prevented from delivering on its own plans as a standalone company. Shares in Next Fifteen fall 1.9% on Friday.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
24 Jul 2020 17:23

IN BRIEF: ValiRx Raises GBP300,700 From Broker Option

IN BRIEF: ValiRx Raises GBP300,700 From Broker Option

Read more
23 Jul 2020 18:02

UK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump

UK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump

Read more
16 Jul 2020 15:57

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
6 Jul 2020 18:19

IN BRIEF: ValiRx Outlines Oncology, Women's Health Focus

IN BRIEF: ValiRx Outlines Oncology, Women's Health Focus

Read more
6 Jul 2020 09:31

ValiRx looks to build on portfolio of drug candidates

(Sharecast News) - Medicines developer ValiRx said on Monday that it was looking to build on its existing portfolio of drug candidates and grow a pipeline of innovative, early-stage projects in the areas of oncology and women's health.

Read more
1 Jul 2020 13:10

IN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall

IN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall

Read more
16 Jun 2020 13:58

IN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement

IN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement

Read more
8 Jun 2020 15:39

ValiRx Delays Annual Results Amid Covid-19 Pandemic

ValiRx Delays Annual Results Amid Covid-19 Pandemic

Read more
2 Jun 2020 12:57

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

Read more
2 Jun 2020 12:03

ValiRx enters collaboration agreement for Covid-19 treatment

(Sharecast News) - Biotechnology oncology company ValiRx has entered into a collaboration agreement with Oncolytika and Black Cat Bio to explore the use of VAL201 in a combination treatment for patients suffering a hyperimmune response to Covid-19.

Read more
29 May 2020 15:02

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

Read more
29 May 2020 12:59

ValiRx offloads non-core IP to DDTech

(Sharecast News) - ValiRx has entered into a deed of assignment with Drug Discovery Technologies (DDTech) for the patents, materials and know-how associated with its non-core intellectual property 'FitBio' and 'TRAC', it announced on Friday.

Read more
27 May 2020 14:20

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

Read more
7 May 2020 14:45

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

Read more
4 May 2020 16:18

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.